2027 Agenda: Day 2 - Tuesday 12 January - PT (Pacific Time, GMT-08:00)
In today’s selective biopharma funding environment, where capital is increasingly concentrated, the panel will explore how companies can navigate the global fundraising landscape and access the right sources of capital. Leading bankers and investors will share perspectives on emerging opportunities, shifting capital flows, and strategies for successful fundraising in today’s challenging environment.
The session will examine how biopharma companies are navigating a new era of alternative financing, tapping sources beyond traditional equity—including government grants and programs such as ARPA-H, NIH and BARDA funding, strategic partnerships, licensing, royalty monetization, structured financing, and other non-dilutive or less-dilutive capital solutions.
Women’s health is actively shifting from a neglected market into a major biopharma priority for biopharma and investors even though it only accounts for 5% of R&D spend. In fact, it represents the biggest untapped growth opportunity in health care. The question is no longer “does this market matter.” The question is “who will move fast enough to own it.”